Pseudo-Grignardr eagents PhLnI (Ln = Yb, Eu), readily prepared by the oxidative addition of iodobenzene to ytterbium or europium metal at À78 8Cint etrahydrofuran (THF) or 1,2-dimethoxyethane (DME), react with ar ange of bulky N,N'-bis(aryl)formamidines to generate an extensive series of Ln II or more rarely Ln III complexes,n amely [Eu(Dipp-, and [Yb(XylForm) 2 I(dme)]·dme (7b){ (Form = ArNCHNAr;X ylForm (Ar = 2,6-Me 2 C 6 H 3 ), MesForm (Ar = 2,4,6-Me 3 C 6 H 2 ), DippForm (Ar = 2,6-iPr 2 C 6 H 3 )}. Reaction of PhEuI and MesFormH in DME consistently gave 2, and reactionw ith XylFormH in THF gave 4.E uropium complexes 1 and 3a are seven-coordinate divalent monomers, whilst 3b is as even-coordinate dme-bridged polymer.C omplex 5a of the smaller Yb II is as ix-coordinate monomer,b ut the related 6 and 7a are six-coordinatei odide-bridged dimers. 4 is at rivalent seven-coordinate hydroxide-bridged dimer,w hereas complexes 5b and 7b are seven-coordinate monomeric Yb III derivatives. Ac haracteristic structural feature is that iodide ligands are cisoid to the formamidinate ligand.T oi llustrate the synthetic scope of the pseudoGrignardr eagents,[ Yb(Ph 2 pz)I(thf) 4 ]( Ph 2 pz = 3,5-diphenylpyrazolate) was oxidised with 1,2-diiodoethane to afford seven-coordinate monomeric pyrazolato-ytterbium (III)
Objectives. To demonstrate safety and efficacy of using different generations of softer Amplatzer ™ devices for ventricular septal defect (VSD) closure to avoid serious complications at follow-up. Background. Transcatheter closure of perimembranous ventricular septal defects (PmVSD) is a well-established procedure; however, it is associated with unacceptable incidence of complete heart block. Great advantages have been achieved by using softer devices for VSD transcatheter closure. e first and second generation of Amplatzer ™ occluders (AVP II, ADO, and ADO II) seem to offer a safe and attractive alternative for this procedure. ese devices can be delivered using either an arterial (retrograde) or venous (prograde) approach. Methods and Results. Patients with congenital PmVSD who underwent transcatheter closure using ADO, ADO II, and AVP II devices were included. Primary end point was to determine efficacy and safety of these generations of devices and to determine the incidence of complications at follow-up (complete AV block and aortic/tricuspid/mitral regurgitation). One hundred and nineteen patients underwent VSD closure at a median age of 5 years (8 months-54 years). During the catheterization, there were only minor complications and at follow-up of 36 ± 25.7 months (up to 99 months), the closure rate was high of 98.3% and freedom from AV block was 100%. Conclusions. e use of softer Amplatzer ™ devices is a good alternative to achieve PmVSD closure safely with no risk of AVB during the procedure or at midterm follow-up.
A series of rare earth biphenolate complexes of the general form [Ln(mbmp)(mbmpH)(thf)3] (Ln = Y (1), Nd (2), Gd (3), Dy (4), Er (5), Tm (6) and Lu (7)) have...
Transcatheter closure of ASDs in children and adolescents was feasible and safe in the first 4 years experience in our centers, with good short-term outcome. Balloon sizing is not necessary for transcatheter closure of secundum ASD. Multiple defects can be safety closed by a single device.
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to their use in developing countries.
Aim. This study aimed to evaluate the efficacy of low dose Sofosbuvir along with Daclatasvir in the management of HCV infection in end-stage renal disease (ESRD) patients.
Methods. A total of 82 HCV positive patients on ESRD were included in this study. The patients were observed for six months without antiviral drugs. Patients who remained seropositive were divided into two groups. The first group included 26 (37%) patients who were treated with half-dose Sofosbuvir 200 mg and Daclatasvir 60 mg and the second group consisted of 44 (63%) patients who have been treated with full-dose Sofosbuvir 400 mg and Velpatasvir 100 mg irrespective of HCV infection genotype for 12 weeks also.
Results. 12 (14%) patients became seronegative spontaneously. All patients (100%) of both groups achieved sustained virological response with undetectable HCV RNA in 12 weeks of the treatment. There were nonsignificant gastrointestinal side effects in the full dose Sofosbuvir group. All patients tolerated the DAAs well. No patient discontinued antiviral therapy due to side effects
Conclusion. In this study, the spontaneous seroconversion of HCV was 14%. Low-dose Sofosbuvir along with Daclatasvir was safe and as effective as full-dose Sofosbuvir and Velpatasvir in the treatment of HCV in ESRD patients. Low-dose Sofosbuvir regimen can be recommended for HCV infection treatment in ESRD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.